Description

Pfizer’s competitive research grant program supports independent studies assessing aztreonam-avibactam (ATM-AVI) treatment in adult patients with suspected or documented Stenotrophomonas maltophilia infections in real-world clinical settings. The program focuses on clinical effectiveness, microbiological outcomes, and healthcare resource utilization among patients treated with ATM-AVI.

Proposals may include special populations, including immunocompromised patients with haemato-oncological conditions or solid organ transplants, and populations at increased infection risk, such as people with cystic fibrosis. The initiative addresses research gaps in bacterial infectious disease and supports Pfizer’s broader goal of improving patient outcomes in areas of unmet medical need. Pfizer makes grant decisions through internal review, while the grantee retains responsibility for study design, implementation, sponsorship, and conduct.